KLF11 in Extracellular Vesicles Derived from adMSCs Inhibits Colorectal Cancer via Suppressing SOAT1-Mediated Lipogenesis.
Yang F., Yu H., Ni J., Sun Y., Zhu X., Wang H.
Laboratory Study, published in Mol Cell Biol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Mol Cell Biol (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42446292
- DOI
- 10.1080/10985549.2026.2685572
Abstract (original English)
Colorectal cancer (CRC) remains one of the most frequently diagnosed and lethal malignancies. Recent studies showed that either adipose-derived mesenchymal stem cells (adMSCs) or the extracellular vesicles (EVs) they secrete retarded CRC progression. Here, we investigated the mechanism underlying the role of adMSCs-EVs in CRC. Here, we found that Krüppel-like factor 11 (KLF11) was upregulated in adMSCs-EVs. adMSCs-EVs sh-KLF11 (EVs derived from KLF11-depleted adMSCs) effectively promoted lipogenesis, cell viability, proliferation, migration, and invasion of CRC cells, and accelerated tumor growth in mice. Furthermore, KLF11 carried by adMSCs-EVs dampened the PI3K/AKT signaling pathway by transcriptionally repressing sterol o-acyltransferase 1 (SOAT1) expression. SOAT1 knockdown blocked the enhanced lipogenesis, proliferation, migration and invasion induced by adMSCs-EVs sh-KLF11 . In conclusion, KLF11 derived from adMSCs-EVs inactivated the PI3K/AKT signaling pathway by transcriptionally downregulating SOAT1, therefore suppressing lipogenesis and malignant progression of CRC.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.